Please provide your email address to receive an email when new articles are posted on . Initiating single-inhaler triple therapy for COPD, compared with multiple-inhaler triple therapy, resulted in ...

Please provide your email address to receive an email when new articles are posted on . Yet, overall, adherence and persistence remained relatively low, indicating a need for better patient education, ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

The IMPACT and ETHOS trials showed that single-inhaler triple therapy significantly reduce the rate of COPD exacerbation and mortality compared with dual bronchodilators. Findings are from an ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...

Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status and ...

Recently, the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older.

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD. Jeffrey D. Dunn ...

* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD * TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY ...